

Vol. 8 No. 3 Desember 2021



Jurnal Farmasi dan Ilmu Kefarmasian Indonesia

E-ISSN: 2580-8303

P-ISSN: 2406-9388



DITERBITKAN OLEH:
FAKULTAS FARMASI UNIVERSITAS AIRLANGGA berkolaborasi dengan
IKATAN APOTEKER INDONESIA (IAI) PENGURUS DAERAH JAWA TIMUR



Terakreditasi SINTA 2
No: B/1796/E5.2/KI.02.00/2020



Home Editorial Team

Editorial Team



Elida Zairina, S.Si., MPH., PhD., Apt

Editor in Chief

Universitas Airlangga, Indonesia



-

-

56127288100



5986180



Suciati, S.Si., M.Phil., PhD., Apt

Editorial Board

Universitas Airlangga, Indonesia



-

-

36453244400



5987657



Dr. rer. nat Maria Lucia Ardhani D. L., S.Si., MPharm, Apt

Editorial Board

Universitas Airlangga, Indonesia



-

-

35573993500



5986185



Didik Setiawan, Ph.D., Apt

Editorial Board

Universitas Muhammadiyah Purwokerto, Indonesia



-

-

56543713300



5972747



Dr. Susi Ari Kristina, M.Kes., Apt

Editorial Board

Universitas Gadjah Mada, Indonesia



-

-

56626120200



6001684



Dr. Ariyanti Suhita Dewi, S.Si., M.Sc

Editorial Board

Kementerian Kelautan dan Perikanan, Indonesia



-

-

36159404300



6670048



Dr. Adiah Mhd. Ali

Editorial Board

Universiti Kebangsaan Malaysia, Malaysia



-

-

5514172000



-



Asst. Prof. Dr. Nungruthai Suphrom

Editorial Board

Naresuan University, Thailand



-

-

54388285100



-



Assist. Prof. Dr. rer. nat. Nuttakorn Baisaeng

Editorial Board

University of Phayao, Thailand



-

-

55630412100



-



Debra Dorotea, Ph.D

Editorial Board

Karolinska Institutet, Sweden



-

-

57196217112



-



Deby Fapyane, Ph.D

Editorial Board

Cellugy ApS, Denmark



-

-

55711006200



-



Susmiandri, S.Kom

Administrative Editor

Universitas Airlangga, Indonesia



-

-

-



-

Login

Username *

Password *

Forgot your password?

Keep me logged in

Login

Register

Accredited Sinta II



Instructions

Guide for Reviewers

Guide for Authors

Online Submission

Document Template

Copyright Form

Journal Policy

Focus and Scope

Publication Ethics

Article Processing Charge

Peer Review Process

Peer Review

Editorial Team

Open Access Statement

Archiving

Plagiarism

Copyright

Contact

Old Website

Publisher

This journal has been published by the
Faculty of Pharmacy, Universitas
Airlangga in collaboration with IAI of
East Java



Meet Our Editorial Team



**Elida Zairina, S.Si., MPH.,
Ph.D., Apt**

Editor in Chief

Universitas Airlangga,
Indonesia

-



**Suciati, S.Si., M.Phil.,
Ph.D., Apt**

Editorial Board

Universitas Airlangga,
Indonesia

-



Susmiandri, S.Kom

Assistant Editor

Universitas Airlangga,
Indonesia

-

Read More

Vol. 8 No. 3 (2021): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA

Current Issue



Vol. 8 No. 3 (2021): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA

Published: 2021-11-30

Full Issue

 PDF

Articles

The Effect of Serotonin-Norepinephrine Reuptake Inhibitor Milnacipran on Anxiety-like Behaviors in Diabetic Mice

 Tuhfatul Ulya, Christawan Ardianto, Mahardian Rahmadi

 200-206

 Abstract : 604

 PDF : 307

 PDF

 DOI : 10.20473/jfiki.v8i32021.200-206

Analisis Faktor-Faktor Klinik yang Mempengaruhi Kualitas Hidup Pasien Katarak di Rumah Sakit Dr. YAP, Yogyakarta

 Rizky Hidayaturahmah, Tri Murti Andayani, Susi Ari Kristina

 207-216

 Abstract : 772

 PDF : 590

 PDF

 DOI : 10.20473/jfiki.v8i32021.207-216

Evaluasi Penggunaan Antibiotik pada Pasien Sepsis Neonatus di Rumah Sakit X Purwakarta

 Rani Hendiyani, Wawaimuli Arozal, Hesty Utami Ramadaniati

 217-226


 Abstract : 496

 PDF : 1167

 PDF

 DOI : 10.20473/jfiki.v8i32021.217-226

Karakterisasi Karbamazepin Hasil Rekrystalisasi Berbagai Pelarut Organik dengan Metode Slow Evaporation

 Indra Indra, Rendi Rahman, Rika Yulianti

 227-234

 Abstract : 1724

 PDF : 1688

 PDF

 DOI : 10.20473/jfiki.v8i32021.227-234

Uji Aktivitas Senyawa Bahan Alam terhadap Enzim Mpro pada SARS-CoV-2 Secara In Silico

 Syahrul Hidayat, Afifah Cahyohartoto, Ayu Utami Dewi

 235-241

 Abstract : 841

 PDF : 598

 PDF

 DOI : 10.20473/jfiki.v8i32021.235-241

Molecular Docking of Compounds in Moringa oleifera Lam with Dipeptidyl Peptidase-4 Receptors as Antidiabetic Candidates

 Indah Permata Rendi, Gabriella Josephine Maranata, Hasna Chaerunisa

 242-249

 Abstract : 496

 PDF : 439

 PDF

 DOI : 10.20473/jfiki.v8i32021.242-249

Pengetahaan dan Ketepatan Apoteker dalam Pemusnahan Obat Sisa, Obat Rusak dan Obat Kadaluarasa di Apotek Malang Raya

 Hananditia Rachma Pramestitie , Ratna Kurnia Illahi , Ayuk Lawuningtyas Hariadini

 250-258

 Abstract : 1744

 PDF : 1730



 DOI : 10.20473/jfiki.v8i32021.250-258

In Vitro Antimalarial Activity and Toxicity of Helianthus annuus L. Leaf Extract against Plasmodium falciparum

 Nuriha Marangoh , Suciati Suciati , Wiwied Ekasari

 259-263

 Abstract : 359

 PDF : 183



 DOI : 10.20473/jfiki.v8i32021.259-263

Pengembangan Sediaan Emulgel Antioksidan dan Tabir Surya Mengandung Ekstrak Kulit Buah Cokelat (Theobroma cacao L)

 Sani Ega Priani , Rizki Anggara Permana , Mira Nurseha

 264-270

 Abstract : 809

 PDF : 968



 DOI : 10.20473/jfiki.v8i32021.264-270

Molecular Docking of Mangostin and Sinensetin Derivatives on SUR1-Pancreatic KATP Channel Target as Antidiabetic

 Intan Kris Prasetyanti , Sukardiman Sukardiman , Suharjono Suharjono

 271-276

 Abstract : 372

 PDF : 182



 DOI : 10.20473/jfiki.v8i32021.271-276

Perbandingan Metode Sintesis Senyawa 1-benzil-3-(4-etil-benzoil)urea dan 1-benzil-3-(4-klorometil-benzoil)urea sebagai Calon Obat Antikanker

 Farida Suhud , Daryono Hadi Tjahjono , Tegar Achsendo Yuniarta

 277-283

 Abstract : 417

 PDF : 311



 DOI : 10.20473/jfiki.v8i32021.277-283

Comparative Analysis of Actual Cost and INA CBG Rate in Diabetic Gangrene Inpatients

 Diajeng Putri Kinanti , Umi Athiyah , Yunita Nita

 284-292


 Abstract : 270

 PDF : 174



 DOI : 10.20473/jfiki.v8i32021.284-292

Linguistic Validation of Indonesian Version of the Audit of Diabetes-Dependent Quality of Life Questionnaire

 Putri Amelia Rooswita , Yunita Nita , Elida Zairina

 293-300

 Abstract : 321

 PDF : 225



 DOI : 10.20473/jfiki.v8i32021.293-300

Login

Username *

Password *

[Forgot your password?](#)

Keep me logged in

Login

[Register](#)

Accredited Sinta II

The Effect of Serotonin-Norepinephrine Reuptake Inhibitor Milnacipran on Anxiety-like Behaviors in Diabetic Mice

Tuhfatul Ulya¹, Christmawan Ardianto^{2*}, Mahardian Rahmadi², Dewi Wara Shinta², Junaidi Khotib²

¹Master Program of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

²Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

*Corresponding author: christmawan-a@ff.unair.ac.id

Submitted: 14 September 2020

Accepted: 22 October 2020

Published: 30 November 2021

Abstract

Background: Diabetes mellitus is a chronic disease that causes neuronal plasticity and increased hypothalamic pituitary adrenal (HPA) axis of stress disorders. The change in metabolism is reportedly associated with inadequate response to antianxiety and antidepressant agents. **Objective:** This study aimed to determine the effect of milnacipran antidepressants on anxiety-like behavior in mice with diabetes mellitus. **Methods:** Male ICR mice were divided into naive, stress, diabetes mellitus (DM), DM + stress groups to measure anxiety-like behavior. Diabetes mellitus was induced using alloxan, and electric footshock stress was used as a stressor for 14 consecutive days. Anxiety-like behavior was measured using the light-dark box (LDB) and elevated plus maze (EPM) test at days 0, 7 and 14. The antidepressant milnacipran (MIL) was given for 7 days, on days 8 to 14. On day 14, evaluation of anxiety-like behavior after administration of MIL was carried out in all groups using LDB and EPM tests. **Results:** The results showed that administration of milnacipran effectively ameliorated anxiety-like behavior in the non-DM, but not in the DM group, using the LDB test. A similar result was demonstrated in the EPM test showing the non-DM group's attenuation after milnacipran administration. **Conclusion:** The present results indicate that there is an inadequate attenuation of the anxiety-like behavior after treatment with milnacipran in diabetes conditions.

Keywords: antidepressant, anxiety-like behaviors, diabetes mellitus, electric footshock stress, milnacipran

Abstrak

Pendahuluan: Diabetes melitus merupakan penyakit kronis yang menyebabkan plastisitas saraf dan peningkatan aktivitas *hypothalamic pituitary adrenal (HPA) axis* yang berhubungan dengan gangguan psikologis terkait stres. Gangguan metabolik pada kondisi diabetes dilaporkan memperburuk respon individu dengan gangguan psikologis terkait stres terhadap obat anti-cemas dan antidepresan. **Tujuan:** Penelitian ini bertujuan untuk mengetahui pengaruh pemberian antidepresan milnacipran terhadap perilaku kecemasan mencit diabetes melitus. **Metode:** Mencit ICR jantan dibagi menjadi kelompok naif, stres, diabetes melitus (DM), DM + stres, untuk mengukur *anxiety-like behavior*. Diabetes melitus diinduksi menggunakan aloksan, dan *electric footshock stress* digunakan sebagai stressor selama 14 hari berturut-turut. *Anxiety-like behavior* diukur menggunakan uji *light-dark box (LDB)* dan *elevated plus maze (EPM)* pada hari ke 0, 7, dan 14. Antidepresan milnacipran (MIL) diberikan selama 7 hari, pada hari ke-8 sampai 14. Pada hari ke-14, evaluasi *anxiety-like behavior* setelah pemberian MIL dilakukan pada kelompok naif, stress, stress + MIL, DM + stress, DM + stress + MIL menggunakan uji LDB dan EPM. **Hasil:** Pemberian milnacipran hanya efektif memperbaiki *anxiety-like behavior* pada kelompok non-DM (stres + MIL), tetapi tidak pada kelompok DM dengan uji LDB. Uji EPM menunjukkan hal yang sama, kelompok DM tidak menunjukkan perbaikan *anxiety-like behavior* setelah pemberian milnacipran. **Kesimpulan:** Pemberian antidepresan milnacipran tidak memperbaiki *anxiety-like behavior* pada mencit diabetes mellitus.

Kata kunci: antidepresan, *anxiety-like behavior*, diabetes melitus, *electric footshock stress*, milnacipran

INTRODUCTION

Diabetes mellitus is a metabolic disease that decreases the quality and life expectancy (Qiu *et al.*, 2016). The increasing prevalence of diabetes causes socioeconomic and psychological pressures, a big challenge for individuals (Li *et al.*, 2019). Structural and neurophysiological changes in the central nervous system caused by diabetes is associated with cognitive deficits and psychiatric disorders (Myers *et al.*, 2013; Qiu *et al.*, 2016). In diabetes mellitus, there is a decrease in hippocampal neurogenesis and neuroplasticity changes associated with depression and anxiety disorders (Ho *et al.*, 2013).

Depression is a heterogeneous disorder due to changes in monoamine neurotransmitters in the brain, especially norepinephrine (NE) and serotonin (5-HT) (Li *et al.*, 2020). Depression as comorbid diabetes was classically introduced 300 years ago (Moulton *et al.*, 2015). The likelihood of depression in diabetes mellitus patients ranges from 10 - 15%, two times greater than in the non-diabetic population (Sartorius, 2018). Comorbid depression in diabetes mellitus patients is also associated with poor outcomes. Diabetes mellitus patients with depression have more difficulty controlling blood glucose levels and have unhealthy lifestyles (Li *et al.*, 2019). In vivo studies show that depression is determined by measuring experimental animals anxiety levels (Kamei *et al.*, 2003).

Improvement of mental conditions, glycemic control and good outcomes is commonly obtained through pharmacological therapy, psychotherapy or a combination of both (Li *et al.*, 2019). Various types of drugs that act on the central nervous system have been used clinically as therapeutic agents. However, an effective treatment strategy for anxiety and depression in diabetes mellitus has not been established.

The effectiveness of serotonin noradrenaline reuptake inhibitors (SNRI) on anxiety disorders has been established in clinical trials. However, the therapeutic effect of these drugs varies depending on the type of anxiety disorder (Miyamoto *et al.*, 2004). Milnacipran is an SNRI group that simultaneously inhibits 5-HT and NE reuptake (Bourin *et al.*, 2005). Murthi & Vaillancourt (2019), in their research, proved that 5-HT might also act as a factor in maintaining normoglycemia. The use of SNRI in the animal study of anxiety-like behaviors showed an increase in the frequency and time of mice entering the open arms (Takeuchi *et al.*, 2010). In addition, milnacipran reduces immobility time in stress-induced mice (Mochizuki *et*

al., 2002). However, there is a lack of evidence showing the efficacy of milnacipran on the anxiety-like behavior of diabetic mice. Thus, the present study investigated the effect of milnacipran on anxiety-like behaviors in diabetes mellitus.

This study measured anxiety-like behavior after milnacipran treatment in diabetes mellitus mice using the light-dark box (LDB) and elevated plus maze (EPM) tests. These methods are based on the principle that rodents do not prefer to stay in open spaces and heights (Bisong *et al.*, 2018). The diabetes mellitus model was developed using alloxan. Alloxan induces diabetes through a partial degradation mechanism of pancreatic beta cells, which affects the quality and quantity of insulin (Ighodaro *et al.*, 2017). The electric footshock as a stress stimulus was used to induce anxiety-like behaviors in mice. It is known that many studies effectively produce an adequate anxiety-like state and fear response through inescapable electric foot shock exposure (Silva *et al.*, 2020).

MATERIALS AND METHODS

Materials

Milnacipran hydrochloride (Ace Pharmaceuticals, Japan), alloxan monohydrate (Sigma-Aldrich, Germany), citrate buffer pH 4.5 (Sigma-Aldrich).

Tools

Light dark box test apparatus, elevated plus maze test apparatus, electric footshock apparatus, stopwatch, Easy Touch ® blood glucose monitoring system.

Animals

Male (6 - 10 weeks old) ICR mice, weighing between 26 and 30 g, were used. All mice were maintained at a regulated temperature ($25^{\circ}\text{C} \pm 2^{\circ}\text{C}$) and humidity ($60 \pm 10\%$) in a 12:12 h diffuse light/dark cycle with free access to food and water. All experiments were performed at the Animal Research Laboratory of the Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. The design and conduct of the study were in accordance with Helsinki's guidance on animal welfare. All effort was done to reduce the animal number and suffering.

Experimental design and treatments

Mice were divided into naive, stress, diabetes mellitus (DM), and DM + stress groups in experiment I ($n = 8$). Diabetes mellitus was induced using a single injection of alloxan. An Anxiety-like state was induced by electric footshock stimulus (0.45 mA, 1 s) 30 times with 9-second intervals for 14 consecutive days. Naive mice as the control group received a normal saline

injection and were placed in the electric chamber for 6 minutes a day without shock stimulus. Evaluation of anxiety-like behavior was measured using the light-dark box (LDB) and elevated plus maze (EPM) test at days 0, 7 and 14. In experiment II (n = 12), an evaluation of anxiety-like behavior after administering milnacipran (MIL) was carried out in the naive, stress, stress + MIL, DM + stress, DM + stress + MIL on day 14. The antidepressant milnacipran at a dose of 20 mg/Kg, reportedly effective in ameliorating anxiety-like behavior (Takeuchi *et al.*, 2010) was given for seven days, on days 8 to 14.

Milnacipran was dissolved in saline and administered orally. The drug was given once a day.

Alloxan-induced diabetes mellitus

Mice were induced with diabetes mellitus by injecting alloxan 170 mg/Kg intraperitoneally (Ighodaro *et al.*, 2017). Alloxan monohydrate was dissolved in a citrate buffer pH 4.5. The blood glucose levels of the mice were checked 48 h after injection with a strip test. Mice with blood glucose levels ≥ 200 mg/dL or 11.1 mmol/L are considered to have diabetes mellitus.

The electric footshock stress procedure

Mice were put into a box measuring 18 x 15 cm with a grid floor from steel, the middle of the box was given a bulkhead. Stress was induced by an inescapable electric footshock with a voltage of 0.45 mA, 60 volts, as previously described (Seo, 2018). A set of electric footshocks has a duration of 1 sec, repeated 30 times at 9-sec intervals. The stress-induced group received two sets of electric footshocks per day. Electric footshocks were exposed for 14 days.

Light dark box (LDB) test

The protocol was performed following the previous study (Zhang *et al.*, 2020). The instrument used consists of two boxes separated by a bulkhead and connected by a door (5 x 5 cm). The light box (27 x 18 x 18 cm) is lit with a white 60-watt incandescent bulb. The dark box (18 x 18 x 18 cm) is completely black. Both are equipped with cameras to record the movements of

mice. Mice were placed in a light box facing the door and allowed to explore both boxes for 5 min. The time spent in each box was recorded. The percentage of time spent in the light box was also calculated.

Elevated plus maze (EPM) test

The protocol was performed following the previous study (Walia *et al.*, 2019; Zhang *et al.*, 2020). The apparatus consists of two open and closed arms (each 30 x 6 cm). Closed arm surrounded by 15 cm wall. The arms cover the central area of the maze with a size of 5 x 5 cm. The apparatus is placed 50 cm above the floor. The mice were placed in the centre area, facing the open arms and exploring the arms for 5 minutes. A camera was positioned above the apparatus to record mice activity. The number of entries to the open arm was recorded, and the percentage was calculated. The movement of mice was calculated when all four legs entered the arm.

Statistical analysis

Data are presented as mean \pm SEM. Measurement of anxiety-like behavior using the LDB and EPM tests at several time points were analyzed using the two-way ANOVA test, followed by the Bonferroni post-hoc test. Meanwhile, the measurement of anxiety-like behavior after milnacipran administration was analyzed using the one-way ANOVA test, followed by the Bonferroni post hoc test. The difference was considered significant if $p < 0.05$ (95%).

RESULTS AND DISCUSSION

The effect of stress induction on anxiety-like behaviors

This study observed stress-induced diabetes mellitus mice using the electric footshock method with the light-dark box (LDB) and elevated plus maze (EPM) tests. The LDB test showed that the stress group significantly reduced time spent in the light box compared to the naive group, seen on days 7 and 14. In addition, the DM + stress group also showed the same results compared to the DM group (Figure 1).




Figure 1. The effect of electric footshock stress induction on anxiety-like behaviors in mice with diabetes mellitus measured by light-dark box test (mean ± SEM) of 8 mice. **p < 0.01, ***p < 0.001 vs naive group. #p < 0.05, ##p < 0.01 vs DM group. DM, diabetes mellitus

On the other hand, EPM test results showed no difference in the percentage of open-arm exploration between the stress and naive groups. However, a significant difference was found in the DM + stress

group, which had a lower percentage of open-arm exploration than the inexperienced group at day 14 (Figure 2).




Figure 2. The effect of electric footshock stress induction on anxiety-like behaviors in mice with diabetes mellitus measured by elevated plus-maze test (mean ± SEM) of 8 mice. **p < 0.01 vs naive group. DM, diabetes mellitus

This result suggests that the present method of stress induction successfully induces anxiety-like behavior reflected in LDB, but not the EPM test. This condition might be due to the severity of stress stimulus during installation that may produce a differential anxiety-like response to specific situations, such as light space or open space stimulus. Moreover, it is known that anxiety with complex emotional states may not be generalized as an expression of a single established behavior.

The difference in EPM conditions and equipment was a factor in the different results. Previous studies of stress induction by the electric footshock method in experimental animals 24 and 48 h before measurement showed no difference in the percentage of time spent in

mice in open arms (Grahn *et al.*, 1995). Another study comparing the effectiveness of test results between elevated zero maze (EZM) and EPM during repeated trials showed behavior in EZM remained relatively stable for several trials and was more suitable than EPM for anxiety experiments (Tucker & McCabe, 2017).

However, the results of the two tests in this study indicate that the condition of diabetes mellitus with stress possibly increases anxiety-like behaviors in experimental animals compared to diabetes mellitus and/or naive conditions alone. This result is in accordance with previous studies that showed an increase in the severity of anxiety in streptozotocin-induced diabetes mellitus mice (Yuan *et al.*, 2019).

The effect of milnacipran treatment against anxiety-like behaviors

The results showed that administration of milnacipran effectively ameliorated anxiety-like behavior measured with the LDB test in the non-DM

group (stress + MIL), but not in the DM group (DM + stress + MIL, Figure 3). This result was demonstrated by the increased time spent in the light box only in the stressed group given milnacipran.




Figure 3. The effect of milnacipran on percentage time spent in the light box in diabetes mellitus mice with anxiety-like behaviors, measured by light-dark box test at day 14 (mean ± SEM) of 12 mice. ***p < 0.001 vs naive group. #p < 0.05 vs stress group. DM, diabetes mellitus; MIL, milnacipran

Similarly, the EPM test results showed that milnacipran did not affect the anxiety-like behavior in the stressed DM group. The present study showed no

attenuation in the decreased percentage of open-arm exploration compared to the group without milnacipran administration (Figure 4).




Figure 4. The effect of milnacipran on the percentage of open-arm exploration in diabetes mellitus mice with anxiety-like behaviors was measured by elevated plus maze test at day 14 (mean ± SEM) of 12 mice. **p < 0.01 vs naive group. DM, diabetes mellitus; MIL, milnacipran

Diabetes mellitus has been reported to increase anxiety-like behaviors. Animals with anxious behavior exhibit lower extracellular serotonin levels than normal animals. It is said that decreased serotonin levels is closely associated with anxiety. Furthermore, it is known that there is a change in serotonin activity in diabetic conditions. The animal model for DM exposed to stress stimulus demonstrates lower extracellular serotonin levels in the hypothalamus than those without stress induction and non-diabetic stressed animal (Thorré *et al.*, 1997). In addition, serotonin modulates noradrenaline (NA) activity. A decrease in serotonin

levels is associated with reducing NA levels (Moret *et al.*, 2011). Milnacipran, an anti-anxiety drug used in the present study, is an SNRI drug that inhibits serotonin and NA uptake with the same potency, without any affinity for dopaminergic transporters (Bourin *et al.*, 2005; Li *et al.*, 2020).

The present results show that milnacipran is not effective at attenuating anxiety-like behaviors in diabetes mellitus. The effect of milnacipran may be lowered due to the changes in the brain's serotonin and NA systems. However, it is also possible that increasing the dose of milnacipran may attenuate anxiety-like

behaviors in diabetes mellitus. The study by Takeuchi *et al.* (2010) showed a dose-dependent of milnacipran increased the time spent in open-arms and the number of open-arm entries. Further research is needed to clarify this issue and the exact mechanisms.

Moreover, previous research has shown a correlation between changes in the brain's glial cells of diabetic mice with anxiety phenotypes. In addition, it was reported that astrocyte activation is found in the hippocampus of diabetic mice, the area that contributes to the development of fear memory and depression (Saravia *et al.*, 2002). Studies showed that the marker protein for astrocyte activation, GFAP, is precisely regulated together with the upregulation of IL-6, indicating a neurological inflammatory response in the CNS of diabetic mice (Qiao *et al.*, 2016; Yuan *et al.*, 2019). This condition suggests that anxiety states in diabetes mellitus comprise complex changes in the neurotransmission system that may affect the efficacy of pharmacological treatment. It remains to be explored whether the different classes of antianxiety demonstrate distinctive tolerability for treating anxiety in diabetic conditions.

CONCLUSION

It is concluded that the antianxiety effect of milnacipran has deteriorated in diabetes mellitus mice. Furthermore, it is suggested that there is a differential anxiety-like response from the EPM and LDB method for anxiety measurement.

ACKNOWLEDGMENT

This work was supported by Ministry of Education, Culture, Research and Technology with PDUPT grant (Dr. Chrismawan Ardianto) and Tahir Foundation Professorship funding in 2020. We thank to Ms. Nadiyah for the excellent technical assistance.

REFERENCES

- Bisong, S. A., Nku, C. O., Nwoke, K. U. & Osim, E. E. (2018). Crude Aqueous Leave Extract of *Carica papaya* linn (Pawpaw) Reduced Anxiety and Fear Related Behaviour in cd1 Mice. *European Journal of Pharmaceutical and Medical Research*; 5; 488–493.
- Bourin, M., Masse, F., Dailly, E. & Hascoët, M. (2005). Anxiolytic-like Effect of Milnacipran in the Four-Plate Test in Mice: Mechanism of Action. *Pharmacology Biochemistry and Behavior*; 81; 645–656.
- Grahn, R. E., Kalman, B. A., Brennan, F. X., Watkins, L. R. & Maier, S. F. (1995). The Elevated Plus-Maze is not Sensitive to the Effect of Stressor Controllability in Rats. *Pharmacology, Biochemistry and Behavior*; 52; 565–570.
- Ho, N., Sommers, M. S. & Lucki, I. (2013). Effects of Diabetes on Hippocampal Neurogenesis: Links to Cognition and Depression. *Neuroscience and Biobehavioral Reviews*; 37; 1346–1362.
- Ighodaro, O. M., Adeosun, A. M. & Akinloye, O. A. (2017). Alloxan-Induced Diabetes, a Common Model for Evaluating the Glycemic-Control Potential of Therapeutic Compounds and Plants Extracts in Experimental Studies. *Medicina (Lithuania)*; 53; 365–374.
- Kamei, J., Miyata, S., Morita, K., Saitoh, A. & Takeda, H. (2003). Effects of Selective Serotonin Reuptake Inhibitors on Immobility Time in the Tail Suspension Test in Streptozotocin-Induced Diabetic Mice. *Pharmacology Biochemistry and Behavior*; 75; 247–254.
- Li, H. Q., Chi, S., Dong, Q. & Yu, J. T. (2019). Pharmacotherapeutic Strategies for Managing Comorbid Depression and Diabetes. *Expert Opinion on Pharmacotherapy*; 20; 1589–1599.
- Li, J., Lu, C., Gao, Z., Feng, Y., Luo, H., Lu, T., Sun, X., Hu, J. & Luo, Y. (2020). SNRIs Achieve Faster Antidepressant Effects than SSRIs by Elevating the Concentrations of Dopamine in the Forebrain. *Neuropharmacology*; 177; 1–11.
- Miyamoto, J., Tsuji, M., Takeda, H., Ohzeki, M., Nawa, H. & Matsumiya, T. (2004). Characterization of the Anxiolytic-Like Effects of Fluvoxamine, Milnacipran and Risperidone in Mice Using the Conditioned Fear Stress Paradigm. *European Journal of Pharmacology*; 504; 97–103.
- Mochizuki, D., Tsujita, R., Yamada, S., Kawasaki, K., Otsuka, Y., Hashimoto, S., Hattori, T., Kitamura, Y. & Miki, N. (2002). Neurochemical and Behavioural Characterization of Milnacipran, a Serotonin and Noradrenaline Reuptake Inhibitor in Rats. *Psychopharmacology*; 162; 323–332.
- Moret, C. & Briley, M. (2011). The Importance of Norepinephrine in Depression. *Neuropsychiatric Disease and Treatment*; 7; 9–13.
- Moulton, C. D., Pickup, J. C. & Ismail, K. (2015). The Link between Depression and Diabetes: the Search for Shared Mechanisms. *The Lancet Diabetes and Endocrinology*; 3; 461–471.

- Murthi, P. & Vaillancourt, C. (2019). Placental Serotonin Systems in Pregnancy Metabolic Complications Associated with Maternal Obesity and Gestational Diabetes Mellitus. *BBA-Molecular Basis of Disease*; 1866; 1-8.
- Myers, A. K., Grannemann, B. D., Lingvay, I. & Trivedi, M. H. (2013). Brief Report: Depression and History of Suicide Attempts in Adults with New-Onset Type 2 Diabetes. *Psychoneuroendocrinology*; 38; 2810–2814.
- Qiao, J., Wang, J., Wang, H., Zhang, Y., Zhu, S., Adilijiang, A., Guo, H., Zhang, R., Guo, W., Luo, G., Qiu, Y., Xu, H., Kong, J., Huang, Q. & Li, X. M. (2016). Regulation of Astrocyte Pathology by Fluoxetine Prevents the Deterioration of Alzheimer Phenotypes in an APP/PS1 Mouse Model. *Glia*; 64; 240–254.
- Qiu, Z. K., He, J. L., Liu, X., Zhang, G. H., Zeng, J., Nie, H., Shen, Y. G. & Chen, J. S. (2016). The Antidepressant-Like Activity of AC-5216, a Ligand for 18KDa Translocator Protein (TSPO), in an Animal Model of Diabetes Mellitus. *Scientific Reports*; 6; 1–13.
- Saravia, F. E., Revsin, Y., Gonzalez Deniselle, M. C., Gonzalez, S. L., Roig, P., Lima, A., Homodelarche, F. & De Nicola, A. F. (2002). Increased Astrocyte Reactivity in the Hippocampus of Murine Models of Type 1 Diabetes: the Nonobese Diabetic (NOD) and Streptozotocin-Treated Mice. *Brain Research*; 957; 345–353.
- Sartorius, N. (2018). Depression and Diabetes, Translational Research. *Dialogues in Clinical Neuroscience*; 20; 47–52.
- Seo, J. H. (2018). Treadmill Exercise Alleviates Stress-Induced Anxiety-Like Behaviors in Rats. *Journal of Exercise Rehabilitation*; 14; 724–730.
- Silva, A. I., Holanda, V. A. D., Azevedo Neto, J. G., Silva Junior, E. D., Soares-Rachetti, V. P., Calo, G., Ruzza, C. & Gavioli, E. C. (2020). Blockade of NOP Receptor Modulates Anxiety-Related Behaviors in Mice Exposed to Inescapable Stress. *Psychopharmacology*; 237; 1633–1642.
- Takeuchi, T., Owa, T., Nishino, T. & Kamei, C. (2010). Assessing Anxiolytic-Like Effects of Selective Serotonin Reuptake Inhibitors and Serotonin-Noradrenaline Reuptake Inhibitors using the Elevated Plus Maze in Mice. *Methods and Finding in Experimental and Clinical Pharmacology*; 32; 113–121.
- Thorré, K., Chaouloff, F., Sarre, S., Meeusen, R., Ebinger, G. & Michotte, Y. (1997). Differential Effects of Restraint Stress on Hippocampal 5-HT Metabolism and Extracellular Levels of 5-HT in Streptozotocin-Diabetic Rats. *Brain Research*; 772; 209–216.
- Tucker, L. B. & McCabe, J. T. (2017). Behavior of Male and Female C57Bl/6J Mice is More Consistent with Repeated Trials in the Elevated Zero Maze than in the Elevated Plus Maze. *Frontiers in Behavioral Neuroscience*; 11; 1–8.
- Walia, V., Garg, C. & Garg, M. (2019). NO-sGC-cGMP Signaling Influence the Anxiolytic Like Effect of Lithium in Mice in Light and Dark Box and Elevated Plus Maze. *Brain Research*; 1704; 114–126.
- Yuan, P., Zhang, J., Li, L. & Song, Z. (2019). Fluoxetine Attenuated Anxiety-Like Behaviors in Streptozotocin-Induced Diabetic Mice by Mitigating the Inflammation. *Mediators of Inflammation*; 2019; 1-8.
- Zhang, K., Lu, J. & Yao, L. (2020). Involvement of the Dopamine D1 Receptor System in the Anxiolytic Effect of Cedrol in the Elevated Plus Maze and Light–Dark Box Tests. *Journal of Pharmacological Sciences*; 142; 26–33.



JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA

FAKULTAS FARMASI UNIVERSITAS AIRLANGGA

P-ISSN : 24069388 < > E-ISSN : 25808303

1,14583
Impact Factor

478
Google Citations

S2
Current Accreditation

History Accreditation

2017 2018 2019 2020 2021 2022 2023 2024

Google Scholar Garuda

[Evaluasi Obat Kadaluwarsa, Obat Rusak dan Stok Mati di Puskesmas Wilayah Magelang](#)

Authors : R Nurma Khairani, E Latifah, N Made Ayu Nila Septianingrum [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(1\), 91-97, 2021](#)

2021 [5 cited](#) [S2 Journal](#)

[Penetapan Kandungan Total Fenolik-Flavonoid pada Fraksi Etil Asetat Kulit Batang Kasturi \(Mangifera casturi Kosterman\)](#)

Authors : H Ramadhan, D Permata Rezky, F Fitri Susiani [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(1\), 58-67, 2021](#)

2021 [8 cited](#) [S2 Journal](#)

[Aphrodisiac Activity of Ethanolic Extracts from the Fruits of Three Pepper Plants from Piperaceae Family](#)

Authors : I Kusumawati, S Mahatmaputra, R Hadi, R Rohmania, S Rullyansyah, ... [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(2\), 194-199, 2021](#)

2021 [0 cited](#) [S2 Journal](#)

[Optimasi Kondisi Fermentasi pada Produksi Metabolit Antibakteri dari Bacillus tequilensis BSME Simbiotik Halichondria panicea](#)

Authors : N Pramessti Wardani, A Toto Poernomo, I Isnaeni [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(2\), 187-193, 2021](#)

2021 [0 cited](#) [S2 Journal](#)

[Karakteristik dan Stabilitas Fisik NLC-Koenzim Q10 dalam Sleeping Mask dengan Minyak Nilam](#)

Authors : F Dita Mayangsari, T Erawati, W Soeratri, N Rosita [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(2\), 178-186, 2021](#)

2021 [1 cited](#) [S2 Journal](#)

[Optimasi Aristoflex® AVC dan Propilen Glikol Gel Tabir Surya Rimpang Kunyit dengan Metode Desain Faktorial](#)

Authors : A Sumule, G Pamudji, E Diyah Iksari [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(2\), 168-177, 2021](#)

2021 [0 cited](#) [S2 Journal](#)

[Evaluasi Rasionalitas Penggunaan Obat Neuroprotektif pada Pasien Stroke Iskemik di Rumah Sakit Stroke Nasional Bukittinggi](#)

Authors : D Permatasari, D Ayu Juwita, R Yosmar, J Fajar Rahmat Illahi [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(2\), 162-167, 2021](#)

2021 [1 cited](#) [S2 Journal](#)

[Analisis Boraks pada Jajanan Bakso di Kota Jambi](#)

Authors : S Gustini, D Yulianis, Yulianis, Sutrisno [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(2\), 156-161, 2021](#)

2021 [0 cited](#) [S2 Journal](#)

[The Short Form-6 Dimension \(SF-6D\) Validity and Reliability in Hemodialysis Patients](#)

Authors : A Zulfa Fatihah, T Murti Andayani, N Munif Yasin [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(2\), 150-155, 2021](#)

2021 [0 cited](#) [S2 Journal](#)

[Aktivitas Gel Fraksi Etil Asetat dari Ekstrak Etanol Daun Ubi Jalar Untuk Pengobatan Luka Bakar](#)

Authors : H Fajar Rahmadani, D Pratimasari, M Saiful Amin [Jurnal Farmasi dan Ilmu Kefarmasian Indonesia 8 \(2\), 143-149, 2021](#)

2021 [1 cited](#) [S2 Journal](#)

[View more ...](#)